<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607592</url>
  </required_header>
  <id_info>
    <org_study_id>201507003</org_study_id>
    <nct_id>NCT02607592</nct_id>
  </id_info>
  <brief_title>A Prospective Multi-center Phase III Randomized Controlled Trial</brief_title>
  <acronym>NACA</acronym>
  <official_title>Nadaplatin or Cisplatin Combined With Pemetrexed in the First Line Treatment of Advanced Adenocarcinoma：A Prospective Multi-center Phase III Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the overall toxicity value（OTV）, PFS, ORR and OS
      on advanced adenocarcinoma treated with nadaplatin or cisplatin combined with pemetrexed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall toxicity value</measure>
    <time_frame>1 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>primary free-survival（PFS）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate （ORR）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival（OS）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">293</enrollment>
  <condition>Carcinoma，Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Nadaplatin and Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nadaplatin 80mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin/Pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin and pemetrexed</intervention_name>
    <description>cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）</description>
    <arm_group_label>Cisplatin/Pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nadaplatin+pemetrexed</intervention_name>
    <description>nadaplatin 80mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）</description>
    <arm_group_label>Nadaplatin and Pemetrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient who was confirmed primary adenocarcinoma by pathologic histology or cytology

          2. The TNM staging system according to IASLC2009 was stageIV or those stageIIIB who were
             not fit for operation or radiotherapy

          3. Including one available evaluation lesion at least according to RECIST criteria

          4. Adult patients (≥18 years and ≤75 years). ECOG Performance Status 0 or 1 .Life
             expectancy of at least 12 weeks.Haemoglobin ≥90g/dl, Absolute neutrophil count (ANC)≥
             2x 109/L, platelets ≥100 x 109/L. Total bilirubin ≤upper limit of normal (ULN). ALT
             and AST ≤ 2.5 x ULN. Creatinine clearance ≥60ml/min (calculated according to
             Cockcroft-gault formula).

          5. Patients who had never received any antineoplastic therapy

        Exclusion Criteria:

          1. Patient who has another cancer in recent 5 years,not including basal cell carcinoma or
             cervical carcinoma in situ

          2. Patient with brain metastases whose intracranial pressure symptoms can not control by
             using glucocorticoid or mannitol

          3. Previous radiotherapy（Palliative radiotherapy in order to pain management can be
             excluded）

          4. Patient who has used chemotherapy before(bisphosphonate can be excluded )

          5. Serious uncontrolled systemic disease including active infection,uncontrolled
             hypertension,diabetes,unstable angina,congestive heart failure,myocardial
             infarction,severe arrhythmia which needs drugs,hepatic、renal and metabolic disease

          6. Patient who is allergic to drugs we need to use

          7. Patients who are in pregnancy or lactation

          8. AST or ALT 》2.5 * upper limit of normal (ULN)，and ALP》5*ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>li-kun Chen, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>li-kun chen, Doctor</last_name>
    <phone>13798019964</phone>
    <email>chenlk@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University of cancer center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>li-kun chen, doctor</last_name>
      <phone>13798019964</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004 Jan 15;22(2):330-53. Epub 2003 Dec 22. Review.</citation>
    <PMID>14691125</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li-kun Chen</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>Non-Small-Cell Lung cancer</keyword>
  <keyword>overall toxicity value</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

